Lupin Ltd to acquire brands Ondero and Ondero - Met from Boehringer Ingelheim

Lupin Ltd has entered into Deed of Assignment with Boehringer Ingelheim International GmbH for the acquisition of brands Ondero and Ondero - Met (including trademark rights associated with the brands), which will enable the Company to provide comprehensive and best-in-class treatment options for diabetes management.

The brands relate to medicines for the diabetic segment. Value creation is expected for Lupin's diabetic portfolio.

The cash consideration for the above acquisition will be Euro 26 million.

Shares of Lupin Limited was last trading in BSE at Rs. 695.40 as compared to the previous close of Rs. 682.50. The total number of shares traded during the day was 30101 in over 2110 trades.

The stock hit an intraday high of Rs. 699.15 and intraday low of 676.80. The net turnover during the day was Rs. 20835467.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 BrandAcquisition BoehringerIngelheim Ondero OnderoMet Trademark